<DOC>
	<DOCNO>NCT00843778</DOCNO>
	<brief_summary>To continue assess clinical safety efficacy Certolizumab Pegol add-on therapy stable-dose Disease Modifying Anti-Rheumatic Drugs ( DMARDs )</brief_summary>
	<brief_title>Follow-up Rheumatoid Arthritis ( RA ) Moderate Low Disease Activity Study</brief_title>
	<detailed_description>This Phase IIIB , multi-centre , open-label , follow-up study study C87076 [ NCT00674362 ] design continue ass safety efficacy Certolizumab Pegol . Two different population enter study C87076 [ NCT00674362 ] treat Certolizumab Pegol every two week commercially available indication Rheumatoid Arthritis ( RA ) subject 's country region notice UCB : Population 1 : Are subject failed achieve remission Week 20 and/or Week 24 complete Week 24 assessment study C86076 [ NCT00674362 ] .The Week 24 assessment ( visit 14 ) C87076 [ NCT00674362 ] also entry assessment ( visit 1 ) C87080 . The subject receive Certolizumab Pegol 200 mg every two week . No induction period apply ensure blind study C87076 [ NCT00674362 ] . Population 2 : Are subject achieve remission Week 20 Week 24 , flare Week 24 Week 52 complete Week 52 assessment study C87076 [ NCT00674362 ] . The Week 52 assessment ( visit 26 ) C87076 [ NCT00674362 ] also entry assessment ( visit 1 ) C87080 . Subjects flare prior Week 48 C87076 [ NCT00674362 ] study receive Certolizumab Pegol 200 mg every two week C87080 study . Those flared Week 48 Week 52 , receive respectively 400 mg Certolizumab Pegol three time 400 mg Certolizumab Pegol two week interval part induction phase C87080 study . Thereafter subject enters C87080 study treat 200 mg Certolizumab Pegol every two week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients establish adult rheumatoid arthritis Disease Modifying AntiRheumatic Drugs ( DMARDs ) therapy include C87076 protocol : either fail achieve remission 6 month study treatment flare 6 month study treatment complete study ( C87076 [ NCT00674362 ] ) All concomitant disease pathological condition could interfere impact assessment study treatment Previous clinical trial previous biological therapy could interfere result present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Moderate Low Disease Activity</keyword>
	<keyword>Certolizumab Pegol</keyword>
</DOC>